In October, 2017 Bracco acquired SurgVision, a high-tech innovative start-up company specialized in developing a real-time Fluorescence Image Guided Surgery platform combining a targeted imaging agent and a device for efficient tumor visualization during oncology surgical procedures.
As surgery remains the primary curative option for most solid cancers, a predominant challenge for surgeons during these procedures has been the limitations of visual inspection and digital palpation to distinguish tumors from healthy tissue. Fluorescence Image Guided Surgery represents an innovative intra-operative optical technique aimed at assisting surgeons in distinguishing tumors from surrounding tissue, using a combined infrared camera and contrast agent approach. In this context, SurgVision’s innovative targeting solution is expected to provide significant improvements versus competing modalities and products, due to the extremely advanced features of its optical camera and the very sensitive targeting performance of its new imaging agent.
It's the company's mission to:
- provide researchers and clinicians with a custom designed optical imaging camera system that allows a smooth transition from clinical research to routine applications
- develop integrated optical imaging platforms, including camera, software and target specific tracer(s), for specific disease areas like breast conserving surgery, peritoneal carcinomatosis and esophageal cancer
SurgVision was founded in August 2013, as a spin-off of the Technical University of Munich and it is headquartered in Groningen, The Netherlands, with a development team in Munich, Germany.

www.surgvision.com